Loading patent…
AssigneeLaboratorios Del Dr. Esteve, S.A.
InventorsNuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
Estimating the term…
The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
1-40. (canceled)
A method for treatment or prevention of a disease associated with an infection caused by an enveloped virus in a subject in need thereof, said method comprising administering to said subject an inhibitor of interaction between sialoadhesin and sialyllactose.
A composition or kit-of-parts comprising an antigen-loaded antigen-presenting cell and an inhibitor of interaction between sialoadhesin and sialyllactose.
A conjugate comprising sialoadhesin or a functionally equivalent variant thereof substantially preserving its ability to bind sialyllactose and a therapeutic or diagnostic agent.
A method for delivering a compound of interest to an antigen-presenting cell, said method comprising contacting said antigen-presenting cell with a lipid microparticle comprising said compound of interest, wherein said lipid microparticle comprises at least a molecule containing a sialyllactose moiety.
Dependencies are inferred from the claim text.